R
Roland E. Schmieder
Researcher at University of Erlangen-Nuremberg
Publications - 780
Citations - 85811
Roland E. Schmieder is an academic researcher from University of Erlangen-Nuremberg. The author has contributed to research in topics: Blood pressure & Essential hypertension. The author has an hindex of 97, co-authored 717 publications receiving 78138 citations. Previous affiliations of Roland E. Schmieder include Complutense University of Madrid & University of Regensburg.
Papers
More filters
Journal ArticleDOI
Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial
Murray D. Esler,Henry Krum,Markus P. Schlaich,Roland E. Schmieder,Michael Böhm,Paul A. Sobotka +5 more
TL;DR: The Symplicity HTN-2, a multicenter, randomized trial, demonstrated that catheter-based renal denervation produced significant blood pressure lowering in treatment-resistant patients at 6 months after the procedure compared with control, medication-only patients.
Journal ArticleDOI
Renal Hemodynamics and Renal Function After Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension
Felix Mahfoud,Bodo Cremers,Julia Janker,Britta Link,Oliver Vonend,Christian Ukena,Dominik Linz,Roland E. Schmieder,Lars Christian Rump,Ingrid Kindermann,Paul A. Sobotka,Henry Krum,Bruno Scheller,Markus P. Schlaich,Ulrich Laufs,Michael Böhm +15 more
TL;DR: RD reduced blood pressure, renal resistive index, and incidence of albuminuria without adversely affecting glomerular filtration rate or renal artery structure within 6 months and appears to be a safe and effective therapeutic approach to lower blood pressure in patients with resistant hypertension.
Journal ArticleDOI
Prevention of Atrial Fibrillation by Renin-Angiotensin System Inhibition: A Meta-Analysis
Markus P. Schneider,Tsushung A. Hua,Michael Böhm,Kristian Wachtell,Sverre E. Kjeldsen,Roland E. Schmieder +5 more
TL;DR: This analysis supports the concept of RAS inhibition as an emerging treatment for the primary and secondary prevention of AF but acknowledges the fact that some of the primary prevention trials were post-hoc analyses.
Journal ArticleDOI
Ambulatory Blood Pressure Changes After Renal Sympathetic Denervation in Patients With Resistant Hypertension
Felix Mahfoud,Christian Ukena,Roland E. Schmieder,Bodo Cremers,Lars Christian Rump,Oliver Vonend,Joachim Weil,Martin Schmidt,Uta C. Hoppe,Thomas Zeller,Axel Bauer,Christian Ott,Erwin Blessing,Paul A. Sobotka,Henry Krum,Markus P. Schlaich,Murray D. Esler,Michael Böhm +17 more
TL;DR: RDN reduced office BP and improved relevant aspects of ambulatory BP monitoring, commonly linked to high cardiovascular risk, in patients with true-treatment resistant hypertension, whereas it only affected office BP in pseudoresistant hypertension.
Journal ArticleDOI
23Na Magnetic Resonance Imaging-Determined Tissue Sodium in Healthy Subjects and Hypertensive Patients
Christoph W. Kopp,Peter Linz,Anke Dahlmann,Matthias Hammon,Jonathan Jantsch,Dominik N. Müller,Roland E. Schmieder,Alexander Cavallaro,Kai-Uwe Eckardt,Michael Uder,Friedrich C. Luft,Jens Titze +11 more
TL;DR: 23Na magnetic resonance imaging could have utility in assessing the role of tissue Na+ storage for cardiovascular morbidity and mortality in longitudinal studies, and it is suggested that patients with refractory hypertension had increased tissueNa+ content, compared with normotensive controls.